ALS drug development: Reflections from the past and a way forward

被引：62

作者：

Aggarwal, Swati ^{[1
]}

Cudkowicz, Merit ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Neurol Clin Trials Unit, Dept Neurol, Charlestown, MA 02129 USA

来源：

NEUROTHERAPEUTICS | 2008年 / 5卷 / 04期

关键词：

amyotrophic lateral sclerosis; clinical trial; trial design; conduct; critical review;

D O I：

10.1016/j.nurt.2008.08.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Tremendous advances in our understanding of pathogenesis of amyotrophic lateral sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique compounds have been tested. Nevertheless, riluzole is currently the only treatment that prolongs survival. We present a critical overview of past clinical trials, how therapies are selected for testing in people, challenges with ALS clinical trial design and conduct, and ways to best move forward.

引用

页码：516 / 527

页数：12

共 71 条

[1] Variants in the ALS2 gene are not associated with sporadic amyotrophic lateral sclerosis [J].

Al-Chalabi, A ;

Hansen, VK ;

Simpson, CL ;

Xi, J ;

Hosler, BA ;

Powell, JF ;

McKenna-Yasek, D ;

Shaw, CE ;

Leigh, PN ;

Brown, RH .

NEUROGENETICS, 2003, 4 (04) :221-222

[2] Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease [J].

AlChalabi, A ;

Enayat, ZE ;

Bakker, MC ;

Sham, PC ;

Ball, DM ;

Shaw, CE ;

Lloyd, CM ;

Powell, JF ;

Leigh, PN .

LANCET, 1996, 347 (8995) :159-160

[3] A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].

BENSIMON, G ;

LACOMBLEZ, L ;

MEININGER, V ;

BOUCHE, P ;

DELWAIDE, C ;

COURATIER, P ;

BLIN, O ;

VIADER, F ;

PEYROSTPAUL, H ;

DAVID, J ;

MALOTEAUX, JM ;

HUGON, J ;

LATERRE, EC ;

RASCOL, A ;

CLANET, M ;

VALLAT, JM ;

DUMAS, A ;

SERRATRICE, G ;

LECHEVALLIER, B ;

PEUCH, AJ ;

NGUYEN, T ;

SHU, C ;

BASTIEN, P ;

PAPILLON, C ;

DURRLEMAN, S ;

LOUVEL, E ;

GUILLET, P ;

LEDOUX, L ;

ORVOENFRIJA, E ;

DIB, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :585-591

[4] SUPEROXIDE-DISMUTASE ACTIVITY, OXIDATIVE DAMAGE, AND MITOCHONDRIAL ENERGY-METABOLISM IN FAMILIAL AND SPORADIC AMYOTROPHIC-LATERAL-SCLEROSIS [J].

BOWLING, AC ;

SCHULZ, JB ;

BROWN, RH ;

BEAL, MF .

JOURNAL OF NEUROCHEMISTRY, 1993, 61 (06) :2322-2325

[5]

Brooks BR, 2001, AMYOTROPH LATERAL SC, V2, P60

[6] RAPID PURIFICATION OF EMBRYONIC RAT MOTONEURONS - AN IN-VITRO MODEL FOR STUDYING MND/ALS PATHOGENESIS [J].

CAMU, W ;

HENDERSON, CE .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 1994, 124 :73-74

[7]

Charcot J-M., 1869, 2 CAS ATROPHIE MUSCU

[8] Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis [J].

Cronin, Simon ;

Greenway, Matthew J. ;

Prehn, Jochen H. M. ;

Hardiman, Orla .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (09) :984-986

[9] A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis [J].

Cudkowicz, ME ;

Shefner, JM ;

Schoenfeld, DA ;

Brown, RH ;

Johnson, H ;

Qureshi, M ;

Jacobs, M ;

Rothstein, JD ;

Appel, SH ;

Pascuzzi, RM ;

Heiman-Patterson, TD ;

Donofrio, PD ;

David, WS ;

Russell, JA ;

Tandan, R ;

Pioro, EP ;

Felice, KJ ;

Rosenfeld, J ;

Mandler, RN ;

Sachs, GM ;

Bradley, WG ;

Raynor, EM ;

Baquis, GD ;

Belsh, JM ;

Novella, S ;

Goldstein, J ;

Hulihan, J .

NEUROLOGY, 2003, 61 (04) :456-464

[10] Trial of celecoxib in amyotrophic lateral sclerosis [J].

Cudkowicz, Merit E. ;

Shefner, Jeremy M. ;

Schoenfeld, David A. ;

Zhang, Hui ;

Andreasson, Katrin I. ;

Rothstein, Jeffrey D. ;

Drachman, Daniel B. .

ANNALS OF NEUROLOGY, 2006, 60 (01) :22-31

← 1 2 3 4 5 6 7 8 →